JP2013539767A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539767A5 JP2013539767A5 JP2013533090A JP2013533090A JP2013539767A5 JP 2013539767 A5 JP2013539767 A5 JP 2013539767A5 JP 2013533090 A JP2013533090 A JP 2013533090A JP 2013533090 A JP2013533090 A JP 2013533090A JP 2013539767 A5 JP2013539767 A5 JP 2013539767A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- receptor
- pharmaceutically acceptable
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39354510P | 2010-10-15 | 2010-10-15 | |
| DKPA201070441 | 2010-10-15 | ||
| US61/393,545 | 2010-10-15 | ||
| DKPA201070441 | 2010-10-15 | ||
| US201161491945P | 2011-06-01 | 2011-06-01 | |
| US61/491,945 | 2011-06-01 | ||
| PCT/DK2011/050383 WO2012048710A1 (en) | 2010-10-15 | 2011-10-13 | Combinations of serotonin receptor agonists for treatment of movement disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013539767A JP2013539767A (ja) | 2013-10-28 |
| JP2013539767A5 true JP2013539767A5 (enExample) | 2014-11-27 |
| JP5907975B2 JP5907975B2 (ja) | 2016-04-26 |
Family
ID=44883032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013533090A Expired - Fee Related JP5907975B2 (ja) | 2010-10-15 | 2011-10-13 | 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9186359B2 (enExample) |
| EP (1) | EP2627328B1 (enExample) |
| JP (1) | JP5907975B2 (enExample) |
| KR (1) | KR101825972B1 (enExample) |
| CN (2) | CN103402514B (enExample) |
| AU (1) | AU2011316225B2 (enExample) |
| BR (1) | BR112013009004B1 (enExample) |
| CA (1) | CA2813648C (enExample) |
| CY (1) | CY1118314T1 (enExample) |
| DK (1) | DK2627328T3 (enExample) |
| ES (1) | ES2602973T3 (enExample) |
| HR (1) | HRP20161402T1 (enExample) |
| HU (1) | HUE031661T2 (enExample) |
| IL (1) | IL225758A (enExample) |
| LT (1) | LT2627328T (enExample) |
| MX (1) | MX353625B (enExample) |
| PL (1) | PL2627328T3 (enExample) |
| PT (1) | PT2627328T (enExample) |
| RS (1) | RS55332B1 (enExample) |
| RU (1) | RU2611376C2 (enExample) |
| SI (1) | SI2627328T1 (enExample) |
| WO (1) | WO2012048710A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012163365A1 (en) * | 2011-06-01 | 2012-12-06 | Concit Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
| MY169068A (en) * | 2012-04-18 | 2019-02-12 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| EP2858649B1 (en) * | 2012-06-11 | 2019-10-23 | Psychogenics Inc. | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments |
| HUE039750T2 (hu) | 2014-06-26 | 2019-02-28 | Contera Pharma Aps | Hidroxi-buspiron mozgászavarok kezelésére |
| CN106456622B (zh) * | 2014-07-09 | 2020-05-19 | 皮埃尔法布雷医药公司 | 用贝非拉醇治疗运动障碍的方法 |
| WO2016210431A1 (en) * | 2015-06-26 | 2016-12-29 | Wright State University | Method of treating sepsis-induced myopathy |
| US11013830B2 (en) * | 2015-11-20 | 2021-05-25 | Institut Pasteur | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential |
| CN109689036B (zh) | 2016-07-11 | 2026-06-19 | 康特拉医药股份有限公司 | 用于治疗早晨运动不能的脉冲药物输送系统 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP3897641B1 (en) | 2018-12-20 | 2023-11-15 | Contera Pharma A/S | Treatment of movement disorders |
| US12551481B2 (en) | 2019-12-20 | 2026-02-17 | The Jackson Laboratory | Molecular targets for addiction |
| CN112931397B (zh) * | 2021-01-25 | 2024-02-27 | 江南大学 | 一种帕金森病动物模型的构建方法 |
| JP7804698B2 (ja) * | 2021-05-07 | 2026-01-22 | イーライ リリー アンド カンパニー | ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の味マスキングされた組成物、及びそれを含む経口崩壊錠剤 |
| CN114712365B (zh) * | 2022-06-07 | 2022-08-23 | 山东绿叶制药有限公司 | Trk抑制剂在制备治疗迟发性运动障碍药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4182763A (en) | 1978-05-22 | 1980-01-08 | Mead Johnson & Company | Buspirone anti-anxiety method |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4438119A (en) | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
| US4640921A (en) | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US4687772A (en) | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4777173A (en) | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| US5185329A (en) | 1988-08-30 | 1993-02-09 | Bristol-Myers Squibb Company | Method for treatment of substance addiction |
| US6432956B1 (en) | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
| CZ288351B6 (en) | 1990-06-07 | 2001-05-16 | Astrazeneca Ab | Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof |
| US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| US5431922A (en) | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9209882D0 (en) | 1992-05-07 | 1992-06-24 | Glaxo Lab Sa | Compositions |
| US5484788A (en) | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5637314A (en) | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| US6150365A (en) | 1999-08-05 | 2000-11-21 | Bristol-Myers Squibb Company | Anxiety method |
| GB9928578D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
| WO2002044159A2 (en) * | 2000-11-29 | 2002-06-06 | Eli Lilly And Company | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence |
| WO2002053139A2 (en) * | 2001-01-05 | 2002-07-11 | Eli Lilly And Company | Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders |
| US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| WO2003022269A1 (en) * | 2001-09-12 | 2003-03-20 | Merck Patent Gmbh | Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders |
| DE10353657A1 (de) * | 2003-11-17 | 2005-06-23 | Merck Patent Gmbh | Indolderivate |
| EP1711493A2 (en) | 2004-02-06 | 2006-10-18 | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement | Crystalline forms of zolmitriptan |
| CA2578990A1 (en) * | 2004-09-07 | 2006-03-16 | Pfizer Inc. | Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine |
| US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| WO2007144422A2 (en) * | 2006-06-16 | 2007-12-21 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and l-dopa |
| TW200831479A (en) * | 2006-09-26 | 2008-08-01 | Cytrx Corp | Pharmaceutical compositions and methods for treating diseases |
| WO2008047839A1 (en) * | 2006-10-19 | 2008-04-24 | Dainippon Sumitomo Pharma Co., Ltd. | 5-ht1a receptor agonist |
| WO2008115797A1 (en) * | 2007-03-16 | 2008-09-25 | Pavo, Inc. | Therapeutic compositions and methods |
| CN101686942B (zh) | 2007-06-27 | 2012-09-26 | 韩美药品株式会社 | 用于快速制备用于口服的崩解剂的方法及其产品 |
| WO2009156380A1 (en) | 2008-06-24 | 2009-12-30 | Bjoerklund Anders | Eltoprazine for suppression of l-dopa induced dyskinesias |
| PT2361081T (pt) | 2008-10-14 | 2016-09-05 | Mcneil Ab | Forma de dosagem intra-oral multiporção e seu uso |
| EA026651B1 (ru) | 2009-01-23 | 2017-05-31 | Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. | Фармацевтический или пищевой состав с контролируемым высвобождением и способ его получения |
| SG181896A1 (en) | 2009-12-23 | 2012-07-30 | Map Pharmaceuticals Inc | Novel ergoline analogs |
| WO2012163365A1 (en) | 2011-06-01 | 2012-12-06 | Concit Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
-
2011
- 2011-10-13 CN CN201180060726.9A patent/CN103402514B/zh active Active
- 2011-10-13 KR KR1020137012486A patent/KR101825972B1/ko active Active
- 2011-10-13 RU RU2013120481A patent/RU2611376C2/ru active
- 2011-10-13 US US13/879,128 patent/US9186359B2/en active Active
- 2011-10-13 HU HUE11776071A patent/HUE031661T2/en unknown
- 2011-10-13 CA CA2813648A patent/CA2813648C/en active Active
- 2011-10-13 WO PCT/DK2011/050383 patent/WO2012048710A1/en not_active Ceased
- 2011-10-13 DK DK11776071.0T patent/DK2627328T3/en active
- 2011-10-13 JP JP2013533090A patent/JP5907975B2/ja not_active Expired - Fee Related
- 2011-10-13 EP EP11776071.0A patent/EP2627328B1/en active Active
- 2011-10-13 PT PT117760710T patent/PT2627328T/pt unknown
- 2011-10-13 BR BR112013009004-9A patent/BR112013009004B1/pt not_active IP Right Cessation
- 2011-10-13 ES ES11776071.0T patent/ES2602973T3/es active Active
- 2011-10-13 LT LTEP11776071.0T patent/LT2627328T/lt unknown
- 2011-10-13 PL PL11776071T patent/PL2627328T3/pl unknown
- 2011-10-13 AU AU2011316225A patent/AU2011316225B2/en not_active Ceased
- 2011-10-13 SI SI201131000A patent/SI2627328T1/sl unknown
- 2011-10-13 HR HRP20161402TT patent/HRP20161402T1/hr unknown
- 2011-10-13 CN CN201510595196.8A patent/CN105193809B/zh active Active
- 2011-10-13 RS RS20160985A patent/RS55332B1/sr unknown
- 2011-10-13 MX MX2013004067A patent/MX353625B/es active IP Right Grant
-
2013
- 2013-04-14 IL IL225758A patent/IL225758A/en active IP Right Grant
-
2015
- 2015-11-10 US US14/937,286 patent/US10632116B2/en active Active
-
2016
- 2016-11-14 CY CY20161101164T patent/CY1118314T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5796959B2 (ja) | 関節炎における痛みの治療のためのタペンタドール | |
| JP5907975B2 (ja) | 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ | |
| JP2009511618A (ja) | 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用 | |
| JP6634445B2 (ja) | ブスピロン代謝産物の使用 | |
| ES2966929T3 (es) | Tratamiento de trastornos del movimiento | |
| JP2016505050A5 (enExample) | ||
| JP2009539942A (ja) | ビフェプルノックス及びｌ−ｄｏｐａを含む組み合わせ製剤 | |
| JP2017533956A (ja) | 筋肉痛を含む病態の治療のための組合せ | |
| JP2010241827A (ja) | ５−ヒドロキシトリプタミン１ａレセプター活性増強化合物を用いる運動症状の変動の治療 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JP2008534663A (ja) | 慢性的な痛みおよび疲労を特徴とする症候群の治療のためのネフォパムおよびその類似体の使用 | |
| JP5880913B2 (ja) | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 | |
| US9610285B2 (en) | Compositions for controlling food intake and uses therefor | |
| JP2009539941A (ja) | Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤 | |
| Keystone et al. | THU0228 Tofacitinib, an oral Janus kinase inhibitor: post-hoc analyses of efficacy and safety of monotherapy versus combination therapy in a Phase 3 rheumatoid arthritis population | |
| RU2007129408A (ru) | Способ выращивания поросят в период откорма | |
| US10758505B2 (en) | Therapeutic compositions and methods | |
| WO2023210617A1 (ja) | パーキンソン病治療用医薬組成物 | |
| AU2024357109A1 (en) | Combination of roginolisib with a malt1-gls inhibitor | |
| Gupta | Phentermine and topiramate combination for chronic weight management: a review | |
| JP2010518052A (ja) | 性機能障害の予防および治療に有用な薬物の調製のための、ニューロキニンａのｎｋ２受容体に対する化合物である拮抗薬の使用 | |
| Vanhoutte et al. | THU0229 Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase II a Dose Ranging, Multi-Center Trial | |
| JP2023082719A (ja) | 睡眠改善剤 | |
| Chen et al. | An elderly parkinsonian patient with extreme blood pressure fluctuations | |
| Bautista et al. | Key Concepts |